"For the treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae."@en . . . . . "# Wright AJ: The penicillins. Mayo Clin Proc. 1999 Mar;74(3):290-307. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10090000"@en . . . "Azlocilline"@en . . . " "@en . . . . . "20 to 46% bound to plasma proteins"@en . . . . . " "@en . "A semisynthetic ampicillin-derived acylureido penicillin. [PubChem]"@en . . "Azlocilina"@en . . . . . . . . "Azlocillin"@en . . . . "Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment."@en . "By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, azlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that azlocillin interferes with an autolysin inhibitor."@en . "approved"@en . . "Azlocillin"@en . "Enteric bacteria and other eubacteria"@en . . . "(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"@en . . "Azlocillinum"@en . "37091-66-0"@en . . . . . . . "Not significantly absorbed from the gastrointestinal tract."@en . . .